1. Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. Issue 10328 (5th March 2022) Authors: McGarvey, Lorcan P; Birring, Surinder S; Morice, Alyn H; Dicpinigaitis, Peter V; Pavord, Ian D; Schelfhout, Jonathan; Nguyen, Allison Martin; Li, Qing; Tzontcheva, Anjela; Iskold, Beata; Green, Stuart A; Rosa, Carmen La; Muccino, David R; Smith, Jaclyn A Journal: Lancet Issue: Volume 399:Issue 10328(2022) Page Start: 909 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Validation of a visual analog scale for assessing cough severity in patients with chronic cough. (October 2021) Authors: Martin Nguyen, Allison; Bacci, Elizabeth D.; Vernon, Margaret; Birring, Surinder S.; Rosa, Carmen La; Muccino, David; Schelfhout, Jonathan Journal: Therapeutic advances in respiratory disease Issue: Volume 15(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗